



PA-113. Time Constraints and Treatment Decisions: How Time Allowed for Decision Making Affects Patient Experience in Relapsed Refractory Multiple Myeloma

BACKGROUND

Relapsed refractory multiple myeloma (RRMM) management requires balancing the complexity of treatment options against the urgency of relapse. **This study examines how the time allowed for treatment decisions affects patient satisfaction, comfort, and understanding**, highlighting the need for proactive treatment planning.

METHODOLOGY

This cross-sectional online survey was conducted among **RRMM patients from February 14, 2023 to January 1st, 2024, enrolled in HealthTree.**

- The 30-question survey covered 11 decision-making domains during treatment changes, categorizing time as ≤1 or >1 week for initial and recent choices.
- Participants rated factors using 5-point Likert scales: influence (0–4), satisfaction, comfort, perception of care quality, and treatment utilization (1–5).

Results were reported as numbers and percentages.


CONCLUSION

Most patients have less than a week to make a treatment decision, which often leads them to defer to their doctor and feel influenced by their high-risk status. Patients given >1 week reported greater satisfaction, comfort, and understanding of therapies. **This highlights the need for proactive treatment strategies, supporting the idea that “there is no just-in-time education or trust,”** emphasizing the importance of being prepared for a myeloma relapse.


ACKNOWLEDGEMENT

Our deepest gratitude to the patients and caregivers who share their data and experiences through HealthTree. Your contributions make this research possible.

RESULTS




INFLUENCE OF THE ABILITY TO CONTINUE WORKING WHILE ON TREATMENT IN THE DECISION-MAKING PROCESS



Patients rating of "For your change in therapy (relapse), please indicate to what degree each patient factor (functional/quality of life) went into your decision. (Not including dosage changes): My ability to continue working while on treatment."


Authors: Felipe Flores Quiroz, MD^{1*}, Jennifer M. Ahlstrom, BS¹, Jorge Arturo Hurtado Martínez, MD¹, Julie R. Strain, MMH², Laura Iadeluca PhD², Rachel M. Jensen, BS^{1*}, Cynthia Chmielewski¹, Jay R Hydren, PhD^{1*}, Robert Z. Orlowski MD³, Sagar Lonial, MD⁴, Ola Landgren, MD⁶, Rafael Fonseca, MD⁵, and Saad Usmani, MD⁷.

Organizations: ¹HealthTree Foundation, Lehi, UT; ²GlaxoSmithKline plc, Durham, NC; ³The University of Texas MD Anderson Cancer Center, Houston, TX; ⁴Winship Cancer Institute Of Emory University, Atlanta,GA; ⁵Mayo Clinic, Scottsdale, AZ; ⁶University of Miami Sylvester Comprehensive Cancer Center, Miami, FL; ⁷Memorial Sloan Kettering Cancer Center, New York, NY.



Patients rating of "For your change in therapy (relapse), please indicate to what degree each of your myeloma disease-related factors went into your decision. (Does not include dosage changes): My status as a high-risk patient (based on genetic features)."

INFLUENCE OF POTENTIAL SIDE EFFECT(S) SEVERITY



Patients rating of "For your change in therapy (relapse), please indicate to what degree each patient factor (functional/quality of life) went into your decision. (Not including dosage changes): Potential side effect(s) severity of treatment."

For more information on clinical research collaboration, please contact research@healthtree.org

Disclosures: Fonseca: Consulting: AbbVie, Adaptive, Amgen, Apple, BMS/Celgene, GSK, Janssen, Karyopharm, Pfizer, RA Capital, Regeneron, Sanofi. Scientific Advisory Board: Caris Life Sciences. Board of Directors: Antengene. Patent for FISH in MM - ~\$2000/year Believe in stem cell transplant. Usmani: Research funding: Abbvie, Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda. Consulting: Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Gracell Therapeutics, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio, Ladeluca and Strain: Employee and Stockholder of GlaxoSmithKline plc. Hydren: Research funding from Adaptive Biotechnologies, BioLinRx, Gamida-Cell, Sanofi, GlaxoSmithKline, Regeneron, Pfizer, Johnson and Johnson Innovative Medicine and Takeda Oncology. Ahlstrom: Patient advocacy committee: Pfizer, BMS, Janssen, Takeda Oncology, and Sanofi.

Scan to learn more about how HealthTree can accelerate your research

